On a subcutaneous murine BT474 xenograft model, superior control of tumor growth is demonstrated by targeted pH-triggered vesicles relative to targeted DSPC/cholesterol-based vesicles (35% vs. 19% decrease in tumor volume after 32 days upon initiation of treatment).
I3C, injected intraperitonially (I.P ., significantly inhibited the tumor growth (a 78% decrease in tumor volume) and affected the angiogenesis process by decreasing the microvessel density (CD31 endothelial marker) and complexity.
The average percent decrease in tumor volume was 12.1 ± 7.9%.
Treatment with triparanol, an inhibitor of Hedgehog signaling, resulted in a 60% decrease in tumor volume, a 30% decrease in cellularity, and a 20% reduction in proliferation rate.
Group III treated with free celecoxib resulted in significant decrease in tumor volume compared with control cancer (group II; Fig. 5b).
Decrease in tumor volume (cubic millimeters) after 30 days of treatment (tumor induction 90 days + treatment 30 days = 120 days) (b).
In case of rats (group V) treated with liposomal celecoxib, there was significant decrease in tumor volume with minimal or no change in total body weight compared to control and other treated groups.
Compared to control cells expressing non-silencing small interfering RNA (siRNA), the injection of BMI-1 knockdown cells led to a significantly decrease in tumor volume and size.
The data are expressed as the increase or decrease in tumor volume in mm3 (mm3 = π/6×(larger diameter)× smaller diameter)2).
The decrease in 18F-FLT uptake early post-injection was not accompanied by a decrease in tumor volume as volume of the tumors did not change during the course of therapy.
Compared with control, subcutaneous injection of AECHL-1 to the sites of tumor of mouse melanoma B16F10 implanted in C57BL/6 mice and human breast cancer MCF-7 cells in athymic nude mice resulted in significant decrease in tumor volume.
